Saihong Ignatius Ou

40PUBLICATIONS
199CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Jan 01, 2026
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.

Alexandria T M Lee, Cathleen June Park, Zhaohui Liao Arter

|Nov 06, 2025
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025.

Yanyan Hu, Sai-Hong Ignatius Ou

|Oct 29, 2025
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib.

Sai-Hong Ignatius Ou, Cathleen June Park, Zhaohui Liao Arter

|Oct 07, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.

Alison M Schram, Abdul Rafeh Naqash, Eric B Haura

Pageof 7

Frequent Collaborators

13 joint publications

Misako Nagasaka

6 joint publications

Alexandria T M Lee

6 joint publications

Zhaohui Liao Arter

4 joint publications

Alexander Drilon